石杉碱甲治疗血管性痴呆的临床研究

Huperzine A in treatment of vascular dementia

目的:研究石杉碱甲治疗血管性痴呆的临床疗效和安全性。方法:血管性痴呆患者80例,随机分为石杉碱甲治疗组和对照组,每组40例。两组均给予相同的基础药物治疗,治疗组在基础用药的同时给予石杉碱甲(0.2 mg/d),对照组给予脑复康口服,连续24周。治疗前后由专人进行简易精神状态量表(MMSE)、临床痴呆量表(CDR)及日常生活活动能力量表(ADL)的评定。结果:石杉碱甲治疗24周后,MMSE、ADL评分较治疗前均显著提高(P<0.01,P<0.05),CDR评分显著降低(P<0.05)。对照组治疗24周后,MMSE、ADL评分有升高的趋势,CDR评分减少,但均无统计学意义。治疗后两组相比,MMSE评分(P<0.01)、CDR和ADL评分(P均<0.05)均有统计学差异。结论:石杉碱甲治疗血管性痴呆安全有效,患者的认知功能、痴呆程度和日常生活活动能力均有改善。

Abjective： To study the clinical effects and safety of Huperzine A in treatment of vascular dementia （VaD）. Methods： Eighty patients with VaD were randomly divided into Huperzine A therapy group and control group（each had 40 patients）. Patients in both groups were given general drugs simultaneously, and patients in therapy group was treated with Huperzine A （0.2 nag/d） and in control group were treated with Piracetam. Before and 12, 24 weeks after treatment, the mini mental status examination （MMSE）, clinical dementia rate （CDR） and activity of daily living （ADL, using Barthel Index） were measured by the same doctor. Results： After 24 weeks of treatment with Huperzine A, MMSE and ADL elevated （ P 〈 0.01, P 〈 0.05 respectively）, and CDR decreased （ P 〈 0.05） significantly. These scores had no changes in control group. Conclusion： Huperzine A is an effective and safe drug in treatment of VaD.